Hypoglycaemia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:35:32 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Hypoglycaemia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Safety and Effectiveness of VX-880 for Patients with Type 1 Diabetes and Severe Low Blood Sugar Awareness https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-vx-880-for-patients-with-type-1-diabetes-and-severe-low-blood-sugar-awareness/ Wed, 29 Apr 2026 14:58:44 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-vx-880-for-patients-with-type-1-diabetes-and-severe-low-blood-sugar-awareness/ This clinical trial is focused on studying Type 1 Diabetes Mellitus, a condition where the body cannot produce insulin, leading to high blood sugar levels. The study is testing a new treatment called VX-880 solution for infusion, which is a type of cell therapy. This treatment is designed to help people with Type 1 Diabetes who have difficulty recognizing low blood sugar levels, known as impaired hypoglycemic awareness, and who experience severe low blood sugar episodes, also known as severe hypoglycemia.

The purpose of the study is to evaluate how safe and effective the VX-880 treatment is for these patients. Participants in the study will receive the treatment through a process called infusion, where the solution is delivered directly into the body. The study will monitor participants over time to see how well they tolerate the treatment and whether it helps them manage their diabetes better. This includes checking if they can reduce or stop using insulin and if they experience fewer episodes of severe low blood sugar.

Throughout the study, participants will be closely observed to ensure their safety and to track any changes in their health. The study aims to provide valuable information on whether VX-880 can be a beneficial treatment option for people with Type 1 Diabetes who struggle with severe low blood sugar and impaired awareness of these episodes.

]]> Study on Sotagliflozin for Treating Low Blood Sugar After Weight Loss Surgery in Patients with Post-Bariatric Hypoglycemia https://clinicaltrials.eu/trial/study-on-sotagliflozin-for-treating-low-blood-sugar-after-weight-loss-surgery-in-patients-with-post-bariatric-hypoglycemia/ Wed, 29 Apr 2026 14:23:08 +0000 https://clinicaltrials.eu/trial/study-on-sotagliflozin-for-treating-low-blood-sugar-after-weight-loss-surgery-in-patients-with-post-bariatric-hypoglycemia/ This clinical trial is focused on studying the effects of the medication sotagliflozin on a condition known as post-bariatric hypoglycemia. This condition can occur in individuals who have undergone a type of weight-loss surgery called Roux-en-Y gastric bypass (RYGB). After this surgery, some people experience episodes of low blood sugar, or hypoglycemia, which can happen after eating. The study aims to understand how sotagliflozin, a medication taken as a film-coated tablet, might help manage these low blood sugar episodes.

Participants in the study will receive two different treatments in a random order. One treatment involves taking sotagliflozin, and the other involves taking a placebo, which looks like the medication but does not contain the active ingredient. Each treatment period will last for four weeks. The study is designed to be double-blind, meaning neither the participants nor the researchers will know which treatment is being given at any time, to ensure unbiased results.

The purpose of the study is to investigate how sotagliflozin affects blood sugar levels and fluctuations in people who have had RYGB surgery and experience post-bariatric hypoglycemia. By comparing the effects of sotagliflozin with the placebo, researchers hope to determine if sotagliflozin can help reduce the frequency and severity of low blood sugar episodes in these individuals. The study will continue until March 2026, with recruitment expected to start in September 2024.

]]>